Nintedanib: from discovery to the clinic
- PMID: 25474320
- DOI: 10.1021/jm501562a
Nintedanib: from discovery to the clinic
Abstract
Nintedanib (BIBF1120) is a potent, oral, small-molecule tyrosine kinase inhibitor, also known as a triple angiokinase inhibitor, inhibiting three major signaling pathways involved in angiogenesis. Nintedanib targets proangiogenic and pro-fibrotic pathways mediated by the VEGFR family, the fibroblast growth factor receptor (FGFR) family, the platelet-derived growth factor receptor (PDGFR) family, as well as Src and Flt-3 kinases. The compound was identified during a lead optimization program for small-molecule inhibitors of angiogenesis and has since undergone extensive clinical investigation for the treatment of various solid tumors, and in patients with the debilitating lung disease idiopathic pulmonary fibrosis (IPF). Recent clinical evidence from phase III studies has shown that nintedanib has significant efficacy in the treatment of NSCLC, ovarian cancer, and IPF. This review article provides a comprehensive summary of the preclinical and clinical research and development of nintedanib from the initial drug discovery process to the latest available clinical trial data.
Similar articles
-
Nintedanib: a novel therapeutic approach for idiopathic pulmonary fibrosis.Respir Care. 2014 Sep;59(9):1450-5. doi: 10.4187/respcare.03023. Epub 2014 Apr 29. Respir Care. 2014. PMID: 24782550 Review.
-
Nintedanib modulates surfactant protein-D expression in A549 human lung epithelial cells via the c-Jun N-terminal kinase-activator protein-1 pathway.Pulm Pharmacol Ther. 2015 Jun;32:29-36. doi: 10.1016/j.pupt.2015.03.001. Epub 2015 Apr 2. Pulm Pharmacol Ther. 2015. PMID: 25843005
-
Intedanib, a triple kinase inhibitor of VEGFR, FGFR and PDGFR for the treatment of cancer and idiopathic pulmonary fibrosis.IDrugs. 2010 May;13(5):332-45. IDrugs. 2010. PMID: 20432191 Review.
-
Nintedanib in non-small cell lung cancer: from preclinical to approval.Ther Adv Respir Dis. 2015 Aug;9(4):164-72. doi: 10.1177/1753465815579608. Epub 2015 Apr 7. Ther Adv Respir Dis. 2015. PMID: 25855060 Review.
-
Anti-fibrotic effects of nintedanib in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis.Respir Res. 2014 Dec 12;15(1):157. doi: 10.1186/s12931-014-0157-3. Respir Res. 2014. PMID: 25496490 Free PMC article.
Cited by
-
Advanced Delivery Strategies of Nintedanib for Lung Disorders and Beyond: A Comprehensive Review.AAPS PharmSciTech. 2024 Jul 1;25(6):150. doi: 10.1208/s12249-024-02869-9. AAPS PharmSciTech. 2024. PMID: 38954161 Review.
-
Design, synthesis and pharmacological evaluation of 4-(3-chloro-4-(3-cyclopropylthioureido)-2-fluorophenoxy)-7-methoxyquinoline-6-carboxamide (WXFL-152): a novel triple angiokinase inhibitor for cancer therapy.Acta Pharm Sin B. 2020 Aug;10(8):1453-1475. doi: 10.1016/j.apsb.2020.04.002. Epub 2020 Apr 19. Acta Pharm Sin B. 2020. PMID: 32963943 Free PMC article.
-
β-Carboline Alkaloids From the Deep-Sea Fungus Trichoderma sp. MCCC 3A01244 as a New Type of Anti-pulmonary Fibrosis Agent That Inhibits TGF-β/Smad Signaling Pathway.Front Microbiol. 2022 Jul 28;13:947226. doi: 10.3389/fmicb.2022.947226. eCollection 2022. Front Microbiol. 2022. PMID: 35966687 Free PMC article.
-
The protective effect of natural medicines in rheumatoid arthritis via inhibit angiogenesis.Front Pharmacol. 2024 May 31;15:1380098. doi: 10.3389/fphar.2024.1380098. eCollection 2024. Front Pharmacol. 2024. PMID: 38881875 Free PMC article. Review.
-
Novel N-Substituted Amino Acid Hydrazone-Isatin Derivatives: Synthesis, Antioxidant Activity, and Anticancer Activity in 2D and 3D Models In Vitro.Int J Mol Sci. 2021 Jul 21;22(15):7799. doi: 10.3390/ijms22157799. Int J Mol Sci. 2021. PMID: 34360565 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Chemical Information
Medical
Miscellaneous